Medication approval journey

amphetamine (Adderall XR)

Approved for ADHD in children, adolescents and adults

page first published · last updated

Also answers to “the perpetual shortage” — its codename in our videos and posts. The full codebook

FDA approvedStimulantTaper risk: moderate

How this page reads

The page as written, with the clinical terms

Plain language uses the same facts, the same numbers and the same caveats. It does not leave anything out. Quotes from the FDA label are never reworded in either setting.

Before you stop or change your amphetamine dose

Stopping abruptly causes withdrawal effects that can be severe

Stopping a stimulant abruptly after regular use commonly causes a crash — fatigue, low mood, heavy sleep. It is not usually dangerous, but it is worth planning rather than improvising.

we went and looked

claims about amphetamine we went and checked

  • overstateddo adhd stimulants and modafinil all increase dopamine in the brainsaid on Huberman Lab, 2026-10-01; The core of the statement holds up. FDA labels say amphetamines (including the dextroamphetamine that lisdexamfetamine turns into) and methylphenidate block dopamine reuptake and increase dopamine release. The modafinil and armodafinil labels say both drugs bind the dopamine transporter and block dopamine reuptake, and a human PET study measured higher extracellular dopamine after therapeutic doses of modafinil.
  • confirmedis taking someone else's adhd stimulant illegal and risky for addiction and side effects?said on Huberman Lab, 2026-10-01; The claim holds up. In the u.s., having a prescription stimulant you weren't prescribed is a federal crime, and the fda's own 2023 safety notice says nonmedical use is linked to a higher risk of substance use disorder and can lead to overdose and death.
  • confirmeddo stimulants calm children with adhd instead of making them more hyperactive?said on Huberman Lab, 2026-10-01; the speaker is right on the main point: in randomized trials, stimulants given to children with adhd lower hyperactivity and inattention ratings over the short term. they do not make those symptoms worse.
  • misattributedare toddlers on medicaid being put on anti-anxiety drugs in large numberssaid on a Substack newsletter, 2026-03-10; The underlying worry is real and the public record backs it: in the 2025 reporting year the median state documented first-line psychosocial care for only 59.2 percent of children aged 1 to 11 starting an antipsychotic, got both required metabolic blood tests for 29.1 percent of young children on two or more antipsychotic prescriptions, and saw 47.6 percent of children newly prescribed an ADHD medicine again within 30 days. Those are the states' own numbers.

every check quotes one sentence, links the original at the timestamp, and takes each assertion to the primary record. the full list: /checked.

How long the amphetamine trials actually ran

The longest trial behind the amphetamine approval ran 4 weeks.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

People often stay on these drugs for far longer than the trials ran. The trials behind the approval ran 3 to 4 weeks.

That does not mean longer use is unsafe. It does not mean the drug stops working either. It means longer use was never the thing that got tested.

If you have been on it a long time, that is a fair thing to ask your prescriber about.

Boxed warning: abuse, misuse, and addiction

The strongest warning the FDA puts on a label, often called a black box warning. It is reproduced below word for word, not summarised.

This is the strongest warning the FDA can put on a drug label. Some people call it a black box warning. We copied it word for word. We did not shorten it and we did not soften it.

The warning below is about abuse, misuse, and addiction. The label says this drug has a high chance of being abused or misused. That can lead to a substance use disorder, including addiction. Misuse and abuse of stimulants like this one can cause overdose and death. The risk goes up with higher doses. It also goes up with ways of taking it the label does not approve, such as snorting or injecting.

The FDA’s own words follow, copied exactly.

WARNING: ABUSE, MISUSE, and ADDICTION ADDERALL XR ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ADDERALL XR treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, and ADDICTION See full prescribing information for complete boxed warning. ADDERALL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in overdose and death ( 5.1 , 9.2 , 10 ): Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

FDA label effective April 30, 2026 — read the full label on DailyMed

What amphetamine is FDA approved for, and the trials behind it

Approved for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older in 2001, under application NDA 021303. Source: FDA Drugs@FDA.

A double-blind, randomized, placebo-controlled, parallel-group trial in 584 children aged 6 to 12 compared fixed doses of 10 mg, 20 mg, or 30 mg once daily against placebo for three weeks, with significant improvements in teacher-rated attention and hyperactivity at all doses; a 51-patient classroom analogue study gave supporting results. The label also reports 4-week placebo-controlled trials in 327 adolescents and 255 adults.

The FDA approved amphetamine in 2001. The approved use was attention deficit hyperactivity disorder (ADHD). It covers adults and children aged 6 and older. The file number is NDA 021303. The source is Drugs@FDA, the FDA's own database.

The main trial ran three weeks in 584 children aged 6 to 12. It tested a set dose of 10 mg, 20 mg, or 30 mg once a day against a placebo.

People were sorted into groups by chance. Nobody knew who got the drug (randomized, double-blind). Teachers rated attention and overactivity. Every dose did better than the placebo.

A smaller classroom study of 51 patients backed that up. The label also reports 4-week trials against a placebo in 327 teens and 255 adults.

Trials
3 parallel-group placebo-controlled trials
Duration
3 to 4 weeks
Participants
584 children, 327 adolescents, 255 adults
Compared against
Placebo
A double-blind, randomized, placebo-controlled, parallel-group study was conducted in children aged 6 to 12 (N=584) who met DSM-IV ® criteria for ADHD (either the combined type or the hyperactive-impulsive type). Patients were randomized to fixed-dose treatment groups receiving final doses of 10 mg, 20 mg, or 30 mg of ADDERALL XR or placebo once daily in the morning for three weeks.

Verbatim from the amphetamine FDA label, Clinical Studies section, effective April 30, 2026 — read the full label on DailyMed.

Side effects of amphetamine in the approval trials

Incidence among 374 children aged 6 to 12 on Adderall XR versus 210 on placebo in the 3-week trial, for reactions reported by 2% or more of treated patients at a higher rate than on placebo. The label cautions that trial rates cannot be directly compared with trials of other drugs and may not reflect rates observed in practice.

Read the limits first. These numbers come from the 3-week trial in children aged 6 to 12. 374 children took Adderall XR and 210 took a placebo.

The list holds side effects reported by 2 or more out of every 100 children on the drug. It holds them only where they came up more often than on the placebo.

The label warns that you cannot line these rates up against another drug’s trials. It warns that real life may not match them either.

  • Loss of appetite (22% vs 2% on placebo)
  • Insomnia (17% vs 2%)
  • Abdominal pain (14% vs 10%)
  • Emotional lability (9% vs 2%)
  • Vomiting (7% vs 4%)
  • Nervousness (6% vs 2%)
  • Fever (5% vs 2%)
  • Nausea (5% vs 3%)
  • Infection (4% vs 2%)
  • Weight loss (4% vs 0%)
Pediatric patients ages 6 to 12: Most common adverse reactions (≥5% and with a higher incidence than on placebo) were loss of appetite, insomnia, abdominal pain, emotional lability, vomiting, nervousness, nausea, and fever.

From the amphetamine FDA label, Adverse Reactions section, effective April 30, 2026 — DailyMed.

More from the amphetamine label: drug abuse and dependence

  • Schedule II controlled substance

    Adderall XR contains amphetamine, a Schedule II controlled substance. The label states it has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction; that it can be diverted for non-medical use into illicit channels; and that misuse of CNS stimulants can result in overdose and death.

    FDA label, Drug Abuse and Dependence section.

  • Physical dependence and tolerance

    The label states the drug may produce physical dependence and tolerance. Withdrawal signs after abrupt discontinuation or dose reduction following prolonged use include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation.

    FDA label, Drug Abuse and Dependence section.

What people report to the FDA about amphetamine

Read this before the numbers.

Anyone can file an adverse event report — patients, doctors, manufacturers — and nobody verifies that the drug caused what was reported. There is no denominator: tens of millions of prescriptions generate reports at an unknowable rate, and reporting rises with news coverage, not necessarily with harm. Counts below are report volumes, not rates, and cannot be compared between drugs. The FDA itself says not to use this data to make medical decisions — we show it because you deserve to see what is in the public record, with its limits stated plainly.

Read this before the numbers.

Anyone can send a report to the FDA. Patients can. Doctors can. Drug makers can. Nobody checks that the drug caused what the report describes.

There is also no bottom number. Tens of millions of prescriptions turn into reports at a rate nobody knows. Reports go up when a drug is in the news, and that is not the same as more harm.

So these are counts of reports. They are not rates. You cannot use them to compare one drug with another. The FDA itself says not to use this data to make medical choices.

We show it because it is on the public record, and you should get to see it with its limits named.

50,216
reports mentioning amphetamine, all time
24,705
filed as serious (a report-level flag covering every drug and outcome in the report)
filed as serious. That flag covers the whole report, and one report can name more than one drug and more than one outcome.

Most-reported reactions

  • Drug ineffective5,223
  • Fatigue3,508
  • Nausea3,143
  • Headache2,923
  • Anxiety2,703
  • Toxicity to various agents2,287
  • Depression2,270
  • Feeling abnormal2,143
  • Drug abuse1,972
  • Somnolence1,928

“Drug ineffective” ranking this high is worth noticing: a report of not being helped counts as an adverse event too, and people file them in large numbers.

It is worth noticing how high “drug ineffective” ranks. A report that the drug did not help counts as an adverse event too. People file a lot of them.

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, openFDA dataset refreshed 2026-07-30 (the refresh date of the query endpoint, not the date reports run through).

Drug interactions listed on the amphetamine label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

Below is the part of the FDA label that lists other drugs. It is copied word for word.

No list on the web can see what else you take. A pharmacist can. Ask one to check your full list.

Read the label’s interactions section

7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. ( 2.7 , 7.1 ) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. ( 7.1 )

7.1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer ADDERALL XR concomitantly or within 14 days after discontinuing MAOI [see Contraindications ( 4 )] . Serotonergic Drugs Clinical Impact The concomitant use of ADDERALL XR and serotonergic drugs increases the risk of serotonin syndrome. Intervention Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during ADDERALL XR initiation or dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the concomitant serotonergic drug(s) [see Warnings and Precautions ( 5.8 )] . CYP2D6 Inhibitors Clinical Impact The concomitant use of ADDERALL XR and CYP2D6 inhibitors may increase the exposure of ADDERALL XR compared to the use of the drug alone and increase the risk of serotonin syndrome. Intervention Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during ADDERALL XR initiation and after a dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . Alkalinizing Agents Clinical Impact Increase blood levels and potentiate the action of amphetamine. Intervention Coadministration of ADDERALL XR and gastrointestinal or urinary alkalinizing agents should be avoided. Acidifying Agents Clinical Impact Lower blood levels and efficacy of amphetamines. Intervention Increase dose based on clinical response. Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. Intervention Monitor frequently and adjust or use alternative therapy based on clinical response. Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. Intervention Monitor patients for changes in clinical effect and adjust therapy based on clinical response.

7.2 Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations. Allow for an adequate washout period between administration of ADDERALL XR and radioactive diagnostic agents used for dopamine transporter (DAT) visualization. ADDERALL XR can interfere with the test results of a radioactive diagnostic agent (ioflupane I-123) that is used for DAT visualization by binding and internalization of the DAT, which may result in lower DAT in the striatum. This may lead to false-positive diagnostic results.

FDA label for amphetamine, effective April 30, 2026 — DailyMed.

Label history: when this label changes, it is recorded in What changed.

The amphetamine approval, step by step

  1. Step 1

    What the approval was actually based on

    Which studies did the FDA rely on, how long did they run, and who was in them?

    A double-blind, randomized, placebo-controlled, parallel-group study was conducted in children aged 6 to 12 (N=584)... for three weeks... A double-blind, randomized, placebo-controlled, parallel-group study was conducted in adults (N=255) who met DSM-IV criteria for ADHD... or placebo once daily in the morning for four weeks.

    FDA-approved labelling, 14 CLINICAL STUDIES — read the label on DailyMed

    Our reading

    Three weeks in 584 children, four weeks in 327 adolescents, four weeks in 255 adults. Large trials, short trials. One finding on this label deserves more attention than it gets: in both the adolescent and the adult trials the label states there was not adequate evidence that doses above 20 mg/day conferred additional benefit. A great many people are prescribed more than that. This entry is anchored on Adderall XR, not on the 1960 immediate-release application, because the two are different NDAs with different labels.

  2. Step 2

    The approval

    When was it approved, under what application, and by whose review?

    Approved
    October 11, 2001
    Application
    NDA021303
    Review
    STANDARD
    Original sponsor
    Shire (now Takeda)
    Holds it now
    Takeda Pharmaceuticals USA
    Label submissions since
    25

    Source: openFDA Drugs@FDA, original application ORIG-1

  3. Step 3

    What was added after it was on the market

    Which warnings arrived only after millions of people were already taking it?

    • The stimulant boxed warning was rewritten in 2023

      22 years after approval

      In May 2023 the FDA required the boxed warning on the entire prescription stimulant class — amphetamines and methylphenidates both — to be updated. The specific gap it was closing is unusual and worth knowing: the old labels did not adequately say that most people who misuse these medications get them from a family member or a peer, and that sharing them can cause a substance use disorder in the person you share them with.

      This was an update to a warning that already existed, not a new alarm about the medication working. Stimulants remain first-line treatment for ADHD.

      Worth asking

      How should I be storing this, how do we dispose of what I do not use, and how will we monitor whether my dose is still right over time.

      FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions — U.S. Food and Drug Administration (2023)

    • Stimulants and MAOIs: a 14-day gap is written into the amphetamine label as a contraindication

      23 years after approval

      ADHD stimulants and the MAOI antidepressants are both prescribed in psychiatry, and the combination is one of the few written into a label as an outright contraindication rather than a caution.

      Significant findings

      ADDERALL prescribing information (Teva, June 2024), Contraindications: "Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis".

      Drug Interactions: "Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Adderall concomitantly or within 14 days after discontinuing MAOI".

      The two non-psychiatric MAOIs named, linezolid and intravenous methylene blue, are the ones that catch people: an antibiotic and a dye used in surgery and for a rare blood disorder. The same two are named in every SSRI label read for this wave as MAOIs that make the antidepressant contraindicated for the same 14 days.

      Worth asking

      A 14-day rule cuts both ways: stopping the MAOI does not end the interaction, because the enzyme takes about two weeks to regenerate. If you take a stimulant and are ever prescribed linezolid or given methylene blue in hospital, the treating team needs to know about the stimulant, and the stimulant label is the document to point to. The same applies in reverse for anyone switching from an MAOI to a stimulant or an SSRI: the gap is the interaction.

      ADDERALL (mixed amphetamine salts) tablets: FDA-approved prescribing information, Contraindications and Drug Interactions — Teva Pharmaceuticals USA, Inc.; US Food and Drug Administration (2024)

  4. Step 4

    What independent research has found since

    What has been learned by people who were not selling it?

  5. Step 5

    What still is not known

    Which questions you might reasonably have has nobody answered yet?

    • The label says doses above 20 mg/day showed no additional benefit in two of the three trials. What is your dose, and what was the reason for it?
    • Four weeks at the longest. This is often taken every day for decades.
    • The stimulant boxed warning was rewritten in 2023 to address misuse and dependence, twenty-two years after approval.

Deciding about amphetamine?

Open amphetamine (Adderall XR) in veisund

The app has the full approval journey, the resources behind it, and people working through the same questions.

Download on the App StoreGet it on Google Play

Browse the evidence library